Anúncio
Anúncio

VYGR

VYGR logo

Voyager Therapeutics, Inc. Common Stock

4.03
USD
Patrocinado
-0.03
-0.86%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

4.12

+0.09
+2.24%

Relatórios de Lucros VYGR

Rácio de surpresa positiva

VYGR separação 24 de 40 últimas estimativas.

60%

Próximo Relatório

Data do Próximo Relatório
09 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$10.70M
/
-$0.52
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-19.93%
/
+10.64%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+70.45%
/
-11.86%

Voyager Therapeutics, Inc. Common Stock earnings per share and revenue

On 10 de nov. de 2025, VYGR reported earnings of -0.47 USD per share (EPS) for Q3 25, beating the estimate of -0.53 USD, resulting in a 11.45% surprise. Revenue reached 13.37 milhão, compared to an expected 8.02 milhão, with a 66.74% difference. The market reacted with a +0.71% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 14 analistas forecast an EPS of -0.52 USD, with revenue projected to reach 10.70 milhão USD, implying an aumentar of 10.64% EPS, and diminuir of -19.93% in Revenue from the last quarter.
FAQ
For Q3 2025, Voyager Therapeutics, Inc. Common Stock reported EPS of -$0.47, beating estimates by 11.45%, and revenue of $13.37M, 66.74% above expectations.
The stock price moved up 0.71%, changed from $4.23 before the earnings release to $4.26 the day after.
The next earning report is scheduled for 09 de mar. de 2026.
Based on 14 analistas, Voyager Therapeutics, Inc. Common Stock is expected to report EPS of -$0.52 and revenue of $10.70M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio